DelveInsight’s “Multiple System Atrophy (MSA) Pipeline Analysis, 2020” highlights the details of the Multiple System Atrophy Pipeline Landscape Scenario, including disease overview, unmet needs, and ...

The dynamics of the multiple system atrophy treatment market is anticipated to change during the forecast period as companies across the 7MM are diligently working towards the development of novel ...

MASCOT, a global phase III randomized, double-blind, placebo-controlled trial, will assess the efficacy and safety of amlenetug in the treatment of Multiple System Atrophy (MSA) H. Lundbeck A/S ...

Patients with multiple system atrophy (MSA) have more sleep disorders MSA is a rare neurodegenerative disorder characterized by autonomic dysfunction, tremors (parkinsonism) The study provides hope ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Global Clinical Trials Review, 2025" clinical trials has been added to ...

Tiziana's foralumab continues to be safe and well-tolerated, with no drug-related serious side effects after long-term use, ...

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Several age-related neurodegenerative disorders are characterized by the deposition of aberrantly folded proteins. The histopathological hallmark of synucleinopathies is the deposition of ɑ-synuclein ...

Scientists have found a way to distinguish between two progressive neurodegenerative diseases, Parkinson's disease (PD) and multiple system atrophy (MSA). Scientists have found a way to distinguish ...

Gill Wheeler, whose husband Paul has MSA, makes the Radio 4 Appeal on behalf of Multiple System Atrophy Trust. - Freepost BBC Radio 4 Appeal. (That’s the whole address. Please do not write anything ...